Pomalidomide-PEG3-OH
CAS No. 2140807-36-7
Pomalidomide-PEG3-OH( 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-4-[[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]amino]- )
Catalog No. M28649 CAS No. 2140807-36-7
Pomalidomide-PEG3-OH enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 134 | In Stock |
|
| 10MG | 199 | In Stock |
|
| 25MG | 316 | In Stock |
|
| 50MG | 442 | In Stock |
|
| 100MG | 593 | In Stock |
|
| 200MG | 793 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePomalidomide-PEG3-OH
-
NoteResearch use only, not for human use.
-
Brief DescriptionPomalidomide-PEG3-OH enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology.
-
DescriptionPomalidomide-PEG3-OH enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology.
-
In Vitro——
-
In Vivo——
-
Synonyms1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-4-[[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]amino]-
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2140807-36-7
-
Formula Weight405.4
-
Molecular FormulaC19H23N3O7
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOCCOCCOCCNc1cccc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Lavorini F, et al. Antitussive effect of carcainium chloride in patients with chronic cough and idiopathic interstitial pneumonias: A pilot study. Pulm Pharmacol Ther. 2016 Oct;40:91-4.
molnova catalog
related products
-
HPV-E7-N
HPV-E7-N
-
Ralinepag
Ralinepag is a potent, orally bioavailable and non-prostanoid prostacyclin (IP) receptor agonist, with EC50s of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively.
-
MW01-2-151SRM
MW01-2-151SRM is a novel small molecule inhibitor of microglia activation that crosses the blood-brain barrier, has anti-neuroinflammatory effects, attenuates the up-regulation of glial cytokines in models of neuroinflammation, and can be used in studies of traumatic brain injury, Alzheimer's disease, and alginate toxicity.
Cart
sales@molnova.com